Charalampos (Haris) Tzoulis
- Visitor AddressDepartment of Neurology, Haukeland University HospitalRoomTelephone: +47 55975045
- Postal AddressPostboks 78045020 Bergen
Charalampos Tzoulis is a Professor of Neurology and Neurogenetics at the University of Bergen and Haukeland University Hospital, Bergen Norway. As a clinical neurologist, Prof. Tzoulis is an expert on movement disorders and neurodegeneration, including dementia and parkisonism. His research focuses on exploring the role of mitochondrial dysfunction in Parkinson's disease (PD) with the aim to improve patient diagnosis and develop neuroprotective therapies. He is the Principal Investigator of the research group Neuromics at the University of Bergen and co-Director of the Neuro-SysMed Center of Excellence for Clinical Research in Neurological diseases, where he leads the research on PD and other neurodegenerative disorders. Since 2022, he is also the Director of the K.G. Jebsen Center for Translational Research in Parkinson's Disease at UiB.
Neurodegenerative diseases remain an unsolved mystery: https://www.uib.no/en/med/145897/neurodegenerative-diseases-remain-unsolved-mystery
Vil ha hjernebank til Bergen – NRK Vestland
Mystisk hjernesykdom forundrer leger i Canada – NRK Urix – Utenriksnyheter og -dokumentarer
Da demensen tok ordene fra Atle, sluttet mange å snakke til ham. – Det gjorde meg så vondt, sier hans kone. (bt.no)
Han vil finne kur for Parkinson (bt.no)
Åpnet Neuro-SysMed i Bergen - Forskning - Dagens Medisin
– Vi har et problem, tenkte legen da Alice ventet barn (bt.no)
Diabetes drug cuts Parkinson's risk by 28 percent, study finds (medicalnewstoday.com)
Åpner nytt forskningssenter i Bergen: Slik skal de løse ALS-gåten – VG
Parkinson's: How a 'bad' enzyme might protect the brain (medicalnewstoday.com)
Frykter 400 000 med demens i Norge (forskning.no)
Parkinson's disease: Could the answer lie in mitochondria of dopamine cells? (medicalnewstoday.com)
Ny norsk forskning: Diabetesmedisin kan begrense Parkinsons-risiko – VG
Mitochondrial DNA Damage May Be Involved in Parkinson’s Disease… – Parkinson's News Today (parkinsonsnewstoday.com)
Ny norsk forskning kan gi Parkinson-svar – VG
Claes (70) donerer hjernen til forskning (bt.no)
Mitochondria Defects in Brains of Parkinson’s Patients Might Play… – Parkinson's News Today (parkinsonsnewstoday.com)
Forskere prøver alt fra musikk til maskinlæring for å behandle Alzheimers (forskning.no)
Er i gang med å la maskinene ta over for legene: - Nå jobber vi med de digitale modellene, sier norsk forsker - Digi.no
Diabetesmedisin virker mot Parkinsons (forskning.no)
2018 Head of compulsory national course in neurogenetics for training neurologists
2010 – current Advanced training of neurologists in neurogenetics and movement disorders, at national and international (Europe & USA) courses and workshops.
2010 – current Advanced training of movement disorders specialists in botulinum toxin injection
2010 – current Teaching & examining residents for board specialization in Neurology
2007 – current Supervision of pre-graduate thesis projects, University of Bergen, Norway
2006 – current Teaching medical students in clinical neurology, University of Bergen, Norway.
For the most up-to-date publications, please see google scholar, pubmed or ORCID records.
- (2023). Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease. iScience.
- (2022). Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA. Epigenetics. 16 pages.
- (2022). Two independent respiratory chains adapt OXPHOS performance to glycolytic switch. Cell Metabolism. 1792-1808.e6.
- (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism. 396-407.e6.
- (2022). Mitochondrial respiratory chain dysfunction—A hallmark pathology of idiopathic Parkinson’s disease? Frontiers in Cell and Developmental Biology. 1-8.
- (2022). GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Movement Disorders. 1016-1027.
- (2022). Early Forms of α-Synuclein Pathology Are Associated with Neuronal Complex I Deficiency in the Substantia Nigra of Individuals with Parkinson’s Disease. Biomolecules. 1-12.
- (2022). Digital phenotyping by wearable-driven artificial intelligence in older adults and people with Parkinson's disease: Protocol of the mixed method, cyclic ActiveAgeing study. PLOS ONE. 1-19.
- (2022). A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population. NPJ Parkinson's Disease. 1-8.
- (2021). The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: A longitudinal observational study. Neuroscience Letters. 1-7.
- (2021). Stem cell derived astrocytes with POLG mutations and mitochondrial dysfunction including abnormal NAD+ metabolism is toxic for neurons. BioRxiv.
- (2021). Real-world dosing of onabotulinumtoxina and incobotulinumtoxina for cervical dystonia and blepharospasm: Results from trudose and trudose ii. Toxins.
- (2021). NSAID use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study. PLOS ONE. 1-11.
- (2021). Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain. Molecular Neurodegeneration. 1-20.
- (2021). Distinct Mitochondrial Remodeling During Mesoderm Differentiation in a Human-Based Stem Cell Model. Frontiers in Cell and Developmental Biology. 1-12.
- (2021). Chip protein U-box domain truncation affects Purkinje neuron morphology and leads to behavioral changes in zebrafish. Frontiers in Molecular Neuroscience. 1-19.
- (2021). Base excision repair causes age-dependent accumulation of single-stranded DNA breaks that contribute to Parkinson disease pathology. Cell reports. 1-44.
- (2020). Using urine to diagnose large-scale mtDNA deletions in adult patients. Annals of clinical and translational neurology. 1318-1326.
- (2020). Targeting NAD+ in translational research to relieve diseases and conditions of metabolic stress and ageing. Mechanisms of Ageing and Development. 1-6.
- (2020). Mitochondrial respiratory chain deficiency correlates with the severity of neuropathology in sporadic Creutzfeldt-Jakob disease. Acta neuropathologica communications. 1-13.
- (2020). Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci. PLOS ONE. 1-9.
- (2020). LIVE@Home.Path--innovating the clinical pathway for home-dwelling people with dementia and their caregivers: Study protocol for a mixed-method, stepped-wedge, randomized controlled trial. Trials. 1-16.
- (2020). Disease-specific phenotypes in iPSC-derived neural stem cells with POLG mutations. EMBO Molecular Medicine. 1-26.
- (2020). Differential transcript usage in the Parkinson’s disease brain. PLoS Genetics. 1-24.
- (2020). Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition. Acta neuropathologica communications. 1-14.
- (2019). Poly-ADP-ribose assisted protein localization resolves that DJ-1, but not LRRK2 or α-synuclein, is localized to the mitochondrial matrix. PLOS ONE. 1-14.
- (2019). Mitochondrial mechanisms in neurodegeneration.
- (2019). Mitochondrial DNA depletion in sporadic inclusion body myositis. Neuromuscular Disorders. 242-246.
- (2018). Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease. Neurobiology of Aging. 120-127.
- (2018). Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease. Movement Disorders. 1591-1600.
- (2018). Phenotype-genotype correlations in leigh syndrome: New insights from a multicentre study of 96 patients. Journal of Medical Genetics. 21-27.
- (2018). No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease. Brain. e16-e16.
- (2018). Movement disorders in mitochondrial disease: a clinicopathological correlation. Current Opinion in Neurology. 472-483.
- (2018). Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson's disease. Frontiers in Neurology. 1-9.
- (2018). Correction to: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations (Genetics in Medicine, (2017), 19, 11, (1217-1225), 10.1038/gim.2017.35). Genetics in Medicine. 1-1.
- (2018). Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. Alzheimer's & Dementia. 1293-1301.
- (2018). Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease. Neuroscience Letters. 123-126.
- (2018). 3,3'-Diaminobenzidine staining interferes with PCR-based DNA analysis. Scientific Reports. 1-8.
- (2017). The angiogenic switch leads to a metabolic shift in human glioblastoma. Neuro-Oncology. 383-393.
- (2017). Simvastatin is associated with decreased risk of Parkinson disease. Annals of Neurology. 329-330.
- (2017). PNKP Mutations Identified by Whole-Exome Sequencing in a Norwegian Patient with Sporadic Ataxia and Edema. Cerebellum. 272-275.
- (2017). No evidence of ischemia in stroke-like lesions of mitochondrial POLG encephalopathy. Mitochondrion (Amsterdam. Print). 10-15.
- (2017). Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathologica. 409-425.
- (2017). Multippel sklerose - en mitokondriemediert sykdom? Tidsskrift for Den norske legeforening. 274-287.
- (2017). In vitro characterization of six STUB1 variants in spinocerebellar ataxia 16 reveals altered structural properties for the encoded CHIP proteins. Bioscience Reports. 1-12.
- (2017). High-resolution subcellular localization of pathogenic proteins in Parkinson's disease.
- (2017). Glitazone use associated with reduced risk of Parkinson's disease. Movement Disorders. 1594-1599.
- (2017). Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia. Movement Disorders. 241-245.
- (2016). Subcellular Parkinson’s disease-specific alpha-synuclein species show altered behavior in neurodegeneration. Molecular Neurobiology. 1-17.
- (2016). Novel SLC19A3 promoter deletion and allelic silencing in biotin-thiamine-responsive basal ganglia encephalopathy. PLOS ONE.
- (2016). Nigrostriatal denervation sine parkinsonism. Brain.
- (2016). Mitochondrial DNA homeostasis is essential for nigrostriatal integrity. Mitochondrion (Amsterdam. Print). 33-37.
- (2016). Management of dystonia in Europe: A survey of the European network for the study of the dystonia syndromes. European Journal of Neurology. 772-779.
- (2016). Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion (Amsterdam. Print). 32-35.
- (2016). Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature Communications. 11 pages.
- (2016). ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic? European Journal of Neurology. 1188-1194.
- (2015). Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology. 2201-2213.
- (2015). HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia. Proceedings of the National Academy of Sciences of the United States of America.
- (2015). Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Research Notes. 1-5.
- (2015). En mann i 50-årene med høyt ferritinnivå og økende kognitiv svikt. Tidsskrift for Den norske legeforening. 1369-1372.
- (2015). En kvinne i 70-årene med langvarige gangvansker. Tidsskrift for Den norske legeforening.
- (2014). Spastic paraplegia type 7 is associated with multiple mitochondrial DNA deletions. PLOS ONE.
- (2014). Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation. Journal of Neurology. 358-362.
- (2014). Molecular pathogenesis of polymerase gamma-related neurodegeneration. Annals of Neurology. 66-81.
- (2014). A multicenter study on Leigh syndrome: Disease course and predictors of survival. Orphanet Journal of Rare Diseases.
- (2013). Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. Brain. 2393-2404.
- (2013). Progressive striatal necrosis associated with anti-NMDA receptor antibodies. BMC Neurology. 4 pages.
- (2013). Novel SACS mutations identified by whole exome sequencing in a Norwegian family with autosomal recessive spastic ataxia of Charlevoix-Saguenay. PLOS ONE. 5 pages.
- (2013). MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing. Orphanet Journal of Rare Diseases. 10 pages.
- (2012). Polymerase gamma (POLG) associated encephalopathy is characterised by neuronal mtDNA depletion and respiratory complex-I deficiency. European Journal of Neurology. 63-63.
- (2012). Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. Mitochondrion (Amsterdam. Print). 640-643.
- (2012). Leukoencephalopathy with brainstem and spinal cord involvement caused by a novel mutation in the DARS2 gene. Journal of Neurology. 292-296.
- (2012). Leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate (LBSL) caused by a novel mutation in DARS2. European Journal of Neurology. 728-728.
- (2012). Erdheim-Chester disease presenting with an intramedullary spinal cord lesion. Journal of Neurology. 2240-2242.
- (2012). Acute mitochondrial encephalopathy reflects neuronal energy failure irrespective of which genome the genetic defect affects. Brain. 3627-3634.
- (2011). Defining the mitochondrial POLG-related spinocerebellar ataxia and epilepsy in Norway. Advances in Clinical Neurosciences. 20-21.
- (2010). Localized cerebral energy failure in mitochondrial polymerase gamma-associated encephalopathy. European Journal of Neurology. 71-71.
- (2010). Localized cerebral energy failure in DNA polymerase gamma-associated encephalopathy syndromes. Brain. 1428-1437.
- (2010). Differences in RNA processing underlie the tissue specific phenotype of ISCU myopathy. Biochimica et Biophysica Acta - Molecular Basis of Disease. 539-544.
- (2010). Clinical and molecular studies of disease caused by mutations of the mitochondrial DNA polymerase gamma (POLG).
- (2009). Serial Diffusion Imaging in a Case of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes. Stroke. E15-E17.
- (2009). RNA processing differences explain tissue specificity in exercise intolerance myopathy due to ISCU intronic mutation. Neuromuscular Disorders. 623-623.
- (2009). Neuropsychological performance of patients with polg1 mutation and epilepsy: evidence of more pronounced right than left hemisphere dysfunction? Epilepsia. 119-119.
- (2009). Neuropsychological performance in patients with POLG1 mutations and the syndrome of mitochondrial spinocerebellar ataxia and epilepsy. Epilepsy & Behavior. 172-174.
- (2009). Mitochondrial DNA depletion in progressive external ophthalmoplegia caused by POLG1 mutations. Acta Neurologica Scandinavica. 38-41.
- (2009). MRI and neuropathology findings in three patients with the syndrome of mitochondrial spinocerebellar ataxia and epilepsy (MSCAE). Neuropathology and Applied Neurobiology. 20-20.
- (2008). POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain. 818-828.
- (2008). Hereditary spastic paraplegia caused by the novel mutation 1047insC in the SPG7 gene. Journal of Neurology. 1142-1144.
- (2007). MELAS associated with mutations in the POLG1 gene. Neurology.
- (2007). Hereditary spastic paraplegia caused by the novel mutation 1047INSC in the SPG7 gene. European Journal of Neurology. 240-240.
- (2007). Cerebral imaging in mitochondrial spinocerebellar ataxia caused by POLG mutations shows diagnostic specificity and provides insight into disease evolution. European Journal of Neurology. 14-15.
- (2006). The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain. 1685-1692.
- (2006). The clinical spectrum of disease in 26 patients with G1399A or G2243C mutations in the gene encoding the catalytic subunit of mitochondrial DNA-polymerase gamma. European Journal of Neurology. 40-40.
- (2006). The clinical semiology of epilepsy in patients with mitochondriopathy due to polymerasegamma-(POLG) mutations. Epilepsia. 248-248.
More information in national current research information system (CRIStin)